

**Prematurely ended-statement**

EudraCT number	2011-004585-15
Full title of the study	Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes.
Sponsor ID	ENGOT-ov8
Study Contact	Prof. Dr. med. Jalid Sehouli Charité Campus Virchow-Klinikum Klinik für Frauenheilkunde Augustenburger Platz 1 D-13355 Berlin Tel.: +49 (0) 30 450 564002 Fax: +49 (0) 30 450 564922
Sponsor	Charité - Universitätsmedizin Berlin Vertreten durch Prof. Dr. med. Jalid Sehouli Augustenburger Platz 1 D-13353 Berlin
Contact email address	Jalid.sehouli@charite.de
Product	Catumaxomab/ Removab (Fresenius Biotech GmbH, EU)
Date of the early termination of the trial	25/02/2014
Statement on discontinuation of the study	Previous discontinuation of the study due to withdrawal of the market distribution of the study drug.